April 2019—NeoGenomics announced availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy Tecentriq (atezolizumab) used in combination with chemotherapy.
NeoGenomics, 239-768-0600